by Julie Stewart | Feb 26, 2020 | News
Dear Valued Partner: In light of the recent global outbreak of COVID-19 (Novel Coronavirus), Nexus Pharmaceuticals would like to take the opportunity to provide its partners reassurance on Nexus Pharmaceuticals products’ sourcing and manufacturing. The current Nexus...
by Julie Stewart | Nov 19, 2019 | News
Nexus Pharmaceuticals is pleased to announce its certification as a Great Place to Work by the Great Place to Work® Institute. Ninety percent of Nexus employees say the company is a great place to work. The company is proud to employ individuals with a strong work...
by Julie Stewart | Aug 15, 2019 | News
Nexus Pharmaceuticals is pleased to announce the company has ranked #574 in Inc. 5000’s Fastest-Growing Private Companies in America in 2019. Since inception in 2003, and the launch of its first injectable drug in 2017, Nexus Pharmaceuticals has experienced...
by Patrick Weeks | Jul 11, 2019 | News
● The multi-stage, multi-year project is expected to be completed in ten years, with an estimated investment of $250m. ● The only project of its kind in sterile generic injectables in the last 30 years. ● The facility will be located in Pleasant Prairie, Wisconsin,...
by Patrick Weeks | Feb 21, 2019 | News, Product Approvals
Lincolnshire, Ill., February 21, 2019 — Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for Prochlorperazine Edisylate Injection, USP in 10mg/2mL vial. “The launch further expands our generic injectable portfolio...
by Patrick Weeks | Feb 14, 2019 | News, Product Approvals
Lincolnshire, Ill., February 14, 2019 — Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for Dicyclomine Hydrochloride (HCl) Injection, USP in 20mg/2mL vial, the generic equivalent to Bentyl®. Dicyclomine HCl, USP,...
